1:52
MDA - AVI BioPharma Exon-Skipping Clinical Trial
AVI BioPharma opened a phase 2 trial of its exon-skipping drug eteplirsen on Aug. 15, 2011...
published: 15 Aug 2011
author: MySpaceMDA
MDA - AVI BioPharma Exon-Skipping Clinical Trial
AVI BioPharma opened a phase 2 trial of its exon-skipping drug eteplirsen on Aug. 15, 2011, at Nationwide Children's Hospital in Columbus, Ohio. This video features commentary from doctors and families involved in the trial.
58:43
AVI Clinical Trial Update Webinar
Parent Project Muscular Dystrophy's AVI webinar covers a pre-data update on AVI BioPha...
published: 22 Mar 2012
author: ParentProjectMD
AVI Clinical Trial Update Webinar
Parent Project Muscular Dystrophy's AVI webinar covers a pre-data update on AVI BioPharma's Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping. The webinar was lead by Chris Garabedian, the CEO of AVI BioPharma.
4:50
AVI BioPharma (AVII) US Stock to Watch
The AVI BioPharma chart is holding a support level at 75 cents. A bullish harami 2-day can...
published: 09 May 2012
author: AllPennyStocks
AVI BioPharma (AVII) US Stock to Watch
The AVI BioPharma chart is holding a support level at 75 cents. A bullish harami 2-day candle pattern was formed on Monday and Tuesday which will be looking for confirmation on Wednesday to add credence to the support level holding.
19:31
A New Model for Drug Development in Rare Disease: Gaining Approval as a Class / Chris Garabedian, Pr
* How can genetic-based drug development deliver on the promise of personalized medicine *...
published: 04 Feb 2012
author: orphandrugschannel
A New Model for Drug Development in Rare Disease: Gaining Approval as a Class / Chris Garabedian, Pr
* How can genetic-based drug development deliver on the promise of personalized medicine * How can a proven and safe platform enable a pipeline of drugs for a rare disease
4:19
AVI BioPharma, Inc. (NASDAQ:AVII)
The AVII stock chart is holding a support level right on top of the 200 day simple moving ...
published: 28 Feb 2011
author: PennyPayDay
AVI BioPharma, Inc. (NASDAQ:AVII)
The AVII stock chart is holding a support level right on top of the 200 day simple moving average. The indicators are trying to turn and Friday's price movement will catch the eye of technical traders for another potential run similar to the one that occurred through December and January. Keep and eye on the support levels and the resistance at $2.20.
0:38
AVI BioPharma Initiated at Buy at WBB Securities; $3 PT (AVII)
AVI BioPharma, Inc. (NASDAQ:AVII) was initiated with a Speculative Buy rating at WBB Secur...
published: 29 Dec 2010
author: FinancialNewsOnline
AVI BioPharma Initiated at Buy at WBB Securities; $3 PT (AVII)
AVI BioPharma, Inc. (NASDAQ:AVII) was initiated with a Speculative Buy rating at WBB Securities on Wednesday, reports Street Insider. WBB Securitieshas a $3.00 price target set on the firm. Shares of AVI BioPharma are trading 3.86% higher midday at $2.15. AVI BioPharma had sales growth of 0.4% during the last fiscal year. The company has reported $19.0 million in sales over the past 12 months and is expected to report $66.7 million in sales in the next fiscal year. AVI BioPharma has a potential upside of 71.3% based on a current price of $2.14, and an average consensus analyst price target of $3.67.
0:41
News Update: Shares of AVI BioPharma, Inc. Up Pre-Market
Shares of AVI BioPharma, Inc. (NASDAQ:AVII) rallied before market-open Monday morning, fol...
published: 23 Aug 2010
author: TradeTheTrend
News Update: Shares of AVI BioPharma, Inc. Up Pre-Market
Shares of AVI BioPharma, Inc. (NASDAQ:AVII) rallied before market-open Monday morning, following a Reuters report that researches working on a treatment for the Ebola virus said that the lives of infected monkeys were saved from a new tactic used by the biopharmaceutical company. SmarTrend is bullish on shares of AVI BioPharma and our subscribers were alerted to buy on May 18, 2010 at $1.45. The stock has risen 40% since the alert was issued.
0:31
AVI BioPharma Tumbles After Pricing IPO (AVII)
Shares of AVI BioPharma (NASDAQ:AVII) were trading down nearly 18% Friday after the compan...
published: 01 Apr 2011
author: FinancialNewsOnline
AVI BioPharma Tumbles After Pricing IPO (AVII)
Shares of AVI BioPharma (NASDAQ:AVII) were trading down nearly 18% Friday after the company prices a 20 million share public offering at $1.50 per share. That share-offering price is nearly 20% lower than the stock's close yesterday of $1.86 per share. The public offering is expected to close on or about next Thursday, April 6th.
3:02
The Ebola Needle Stick
Dr. Pat Iversen of AVI BioPharma discusses how AVI created a therapeutic for Ebola in five...
published: 15 Sep 2011
author: russopartnersllc
The Ebola Needle Stick
Dr. Pat Iversen of AVI BioPharma discusses how AVI created a therapeutic for Ebola in five days for a Department of Defense researcher accidentally stuck with a needle containing the virus. For more information, visit www.avibio.com
1:35
Rapid Response Success on West Nile Virus
Dr. Pat Iversen of AVI BioPharma discusses how AVI developed a therapeutic to save penguin...
published: 17 Sep 2011
author: russopartnersllc
Rapid Response Success on West Nile Virus
Dr. Pat Iversen of AVI BioPharma discusses how AVI developed a therapeutic to save penguins infected with West Nile Virus at the Milwaukee County Zoo. For more information, visit www.avibio.com
1:39
Contagion
Dr. Pat Iversen of AVI BioPharma discusses the movie 'Contagion' and the reality o...
published: 15 Sep 2011
author: russopartnersllc
Contagion
Dr. Pat Iversen of AVI BioPharma discusses the movie 'Contagion' and the reality of the threat of an emerging infectious disease. For more information, visit www.avibio.com
5:48
Dr. Ed Kaye on ALS and the Incentive Prize Model
Dr. Ed Kaye, the Chief Medical Officer at AVI BioPharma and former Group Vice President an...
published: 17 Oct 2011
author: Prize4Life
Dr. Ed Kaye on ALS and the Incentive Prize Model
Dr. Ed Kaye, the Chief Medical Officer at AVI BioPharma and former Group Vice President and Therapeutic Head for Lysosomal Storage Disorders and Neurodegenerative Diseases at Genzyme Corporation, shares his thoughts on ALS research and the potential of the incentive prize model. This is an extended cut of an interview of Dr. Sato that was featured in the video 'Driving Breakthroughs in ALS Research: Prize4Life and the $1M ALS Biomarker Prize.' That video can be seen here: www.youtube.com For more information on Prize4Life, visit www.prize4life.org
2:05
BioAsia 2011 - Dr. Vinod Kubrekar - Head, Contract services, Intas Biopharma.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia 2011 - Dr. Vinod Kubrekar - Head, Contract services, Intas Biopharma.avi
BioAsia 2011, Hyderabad, India
6:38
Bridging patients and researchers to advance research in rare diseases.
Dr. Ryszard Kole is a researcher whose work led to a discovery that splicing provides a no...
published: 16 Feb 2010
author: eurordis
Bridging patients and researchers to advance research in rare diseases.
Dr. Ryszard Kole is a researcher whose work led to a discovery that splicing provides a novel target for gene based therapies of numerous disorders including rare genetic diseases and metabolic disorders. Hear his views on the importance of bridging patients and researchers to advance research in the field of rare diseases. About Dr. Ryszard Kole Dr. Kole is a pioneer in the use of oligonucleotides for the modulation of splicing. He received his Ph.D. from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. As a postdoctoral fellow in the laboratory of Dr. Sidney Altman at Yale University, he provided early evidence that an RNA component is essential for the activity of a tRNA processing enzyme, RNase P. Subsequent discovery that RNase P is a ribozyme was recognized by a Nobel Prize for Dr. Altman. After joining the Department of Pharmacology at the University of North Carolina at Chapel Hill as a faculty member, Dr. Koles work led to a discovery that splicing provides a novel target for gene based therapies of numerous disorders including cancer, genetic diseases and metabolic disorders such as obesity. He is currently participating in developing this technology into treatment for DMD at AVI Biopharma. More info: www.rarediseaseday.org
10:28
ECYC, IMOS, RVSN, DECK, ALK - Stock Charts - Harry Boxer, TheTechTrader.com
03/14/12 - It was an interesting day on Wall Street on Wednesday. There's rarely a day...
published: 15 Mar 2012
author: thetechtrader
ECYC, IMOS, RVSN, DECK, ALK - Stock Charts - Harry Boxer, TheTechTrader.com
03/14/12 - It was an interesting day on Wall Street on Wednesday. There's rarely a day with such negative technicals, and the market closing next to high. It was up at one point, but, still, it was negative technicals all day. Advance-declines were 3 to 1 on New York Stock Exchange, and the up/down volume about 2 1/2-3 to 1. It looked like a distribution day. We'll see what happens. In the meantime, we'll going over some longs and a few shorts. www.TheTechTrader.com Endocyte, Inc. (ECYT) had a significant price-volume surge. This stock was up 58%, or 2.17, on 12 million shares. It did have a plunged back in December, it based out for the last couple months, and when it had a breakout again, it went up sharply. The next level of resistance is up around 7 1 which is the next target. www.TheTechTrader.com ChipMOS Technologies (IMOS) has made a monster move. Its beautiful base was broken, and we've been pointing this out since January when it was at 6 1 It continues to run, consolidate, spike, flag, snapback with a vengeance from 10.70 to nearly 17, just in the last week, or 6 - 7 sessions. At this point, at the top of the channel, look for some pullback and consolidation, particularly if the market's vulnerable. Don't be in a rush to sell it if you have this stock. Wait for a definitive turndown and play with stops. www.TheTechTrader.com RADVision Ltd. (RVSN) had a key move in the last three sessions, but on Wednesday, it broke out across a little bit of a resistance zone <b>...</b>
8:10
Equity Technical Analysis Review For Friday 10/13/06
Technical analysis of previously mentioned individual stocks trading ideas including; Bruk...
published: 13 Oct 2006
author: thermal1
Equity Technical Analysis Review For Friday 10/13/06
Technical analysis of previously mentioned individual stocks trading ideas including; Bruker BioSciences Corp (BRKR), Ultra Clean Holdings Inc. (UCTT), Vimicro International Corp. (VIMC), NuVasive, Inc. (NUVA), Celgene Corporation (CELG), Fossil Inc. (FOSL), StemCells Inc. (STEM), Archer-Daniels-Midland Co. (ADM), AVI Biopharma Inc. (AVII), Generex Biotechnology Corp. (GNBT), AVI Biopharma Inc. (AVII), Bitstream Inc. (BITS) and a few other stocks. Trend analysis for daytraders and swingtraders of stocks and options. Trading stocks involves risk; this information should not be viewed as trading recommendations.
4:39
BioAsia2011- CEO Conclave- Utkarsh Palnitkar.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia2011- CEO Conclave- Utkarsh Palnitkar.avi
BioAsia 2011, Hyderabad, India
14:18
BioAsia 2011- Exhibition.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia 2011- Exhibition.avi
BioAsia 2011, Hyderabad, India
9:47
BioAsia 2011- Valedictory Ceramony - His Excellency Shri ESL Narasimhan- Governor of AP.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia 2011- Valedictory Ceramony - His Excellency Shri ESL Narasimhan- Governor of AP.avi
BioAsia 2011, Hyderabad, India
6:41
BioAsia 2011 Inaugural- Welcome Address - Prof. Seyed E. Hasnain.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia 2011 Inaugural- Welcome Address - Prof. Seyed E. Hasnain.avi
BioAsia 2011, Hyderabad, India
8:08
BioAsia 2011- Valedictory Ceramony - Prof. D. Balasubramanian.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia 2011- Valedictory Ceramony - Prof. D. Balasubramanian.avi
BioAsia 2011, Hyderabad, India
11:20
BioAsia2011- CEO Conclave- Dr. Bobba Venkatadri.avi
BioAsia 2011, Hyderabad, India...
published: 12 Jul 2011
author: fababioasia
BioAsia2011- CEO Conclave- Dr. Bobba Venkatadri.avi
BioAsia 2011, Hyderabad, India